Neuromuscular DiseasesNeuromuscular DiseasesНервно-мышечные болезни2222-87212413-0443Publishing House ABV Press44510.17650/2222-8721-2021-11-2-17-27LECTURES AND REVIEWSЛЕКЦИИ И ОБЗОРЫAcute and chronic dysimmune polyneuropathies in the context of the COVID-19 pandemic: pathogenesis, features of the clinical picture, diagnosis and therapy (literature review)Острые и хронические дизиммунные полиневропатии в условиях пандемии COVID-19: патогенез, особенности клинической картины, диагностики и терапии (обзор литературы)https://orcid.org/0000-0003-0169-3956KhrulevA. E.ХрулевА. Е.
Russian Federation

10/1 Minin and Pozharsky Square, Nizhny Novgorod 603950 

603950, Нижний Новгород, пл. Минина, 10/1

alexey_khrulev@mail.ruhttps://orcid.org/0000-0001-8346-9354ShiyanovaN. A.ШияноваН. А.
Russian Federation

 24 Sovetskaya St., Pavlovo, Nizhny Novgorod Region 606103 

606103 Нижегородская обл., Павлово, ул. Советская, 24

https://orcid.org/0000-0001-8339-6597SorokoumovaS. N.СорокоумоваС. Н.
Russian Federation

 24 Losinoostrovskaya St., Moscow 1292266/2 Klyuch-Kamyshenskoe Plato St., Novosibirsk 630114 

129226 Москва, ул. Лосиноостровская, 24

630114 Новосибирск, ул. Ключ-Камышенское плато, 6/2 

https://orcid.org/0000-0002-4769-4113 KasatkinD. S.КасаткинД. С.
Russian Federation

  5 Revolutsionnaya St., Yaroslavl 150000 

150000 Ярославль, ул. Революционная, 5

https://orcid.org/0000-0002-6256-3429GrigoryevaV.  N.ГригорьеваВ. Н.
Russian Federation

 10/1 Minin and Pozharsky Square, Nizhny Novgorod 603950 

603950, Нижний Новгород, пл. Минина, 10/1

https://orcid.org/0000-0002-4768-1355 BelyakovK.  M.БеляковК. М.
Russian Federation

10/1 Minin and Pozharsky Square, Nizhny Novgorod 603950 

190 Rodionova St., Nizhny Novgorod 603126 

603950, Нижний Новгород, пл. Минина, 10/1

603126 Нижний Новгород, ул. Родионова, 190

https://orcid.org/0000-0003-3724-1652RomanovaE.   S.РомановаЕ. С.
Russian Federation

 10/1 Minin and Pozharsky Square, Nizhny Novgorod 603950 

603950, Нижний Новгород, пл. Минина, 10/1

https://orcid.org/0000-0001-5143-7366 YankevichD. S.ЯнкевичД. С.
Russian Federation

Build. 2, 25 Petrovka St., Moscow 107031 

107031 Москва, ул. Петровка, 25, стр. 2

Privolzhsky Research Medical UniversityФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава РоссииPavlovsk Central District HospitaГБУЗ НО «Павловская центральная районная больница»Russian State Social UniversityФГБОУ ВО «Российский государственный социальный университет»Novosibirsk Military Institute named after General of the Army I.K. Yakovlev of National Guard Troops of the Russian FederationФГКВОУ ВО «Новосибирский военный институт им. генерала армии И.К. Яковлева войск национальной гвардии Российской Федерации»Yaroslavl State Medical UniversityФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава РоссииNizhny Novgorod Regional Clinical Hospital named after N.A. SemashkoГБУЗ «Нижегородская областная клиническая больница им. Н.А. Семашко»Federal Research and Clinical Center of Intensive Care Medicine and RehabilitologyФГБНУ «Федеральный научно-клинический центр реаниматологии и реабилитологии»1309202111217271309202113092021Copyright ©; 2021, Khrulev A.E., Shiyanova N.A., Sorokoumova S.N.,  Kasatkin D.S., Grigoryeva V. .,  Belyakov K. ., Romanova E.S.,  Yankevich D.S.Copyright ©; 2021, Хрулев А.Е., Шиянова Н.А., Сорокоумова С.Н., Касаткин Д.С., Григорьева В.Н., Беляков К.М., Романова Е.С., Янкевич Д.С.2021Khrulev A.E., Shiyanova N.A., Sorokoumova S.N.,  Kasatkin D.S., Grigoryeva V. .,  Belyakov K. ., Romanova E.S.,  Yankevich D.S.Хрулев А.Е., Шиянова Н.А., Сорокоумова С.Н., Касаткин Д.С., Григорьева В.Н., Беляков К.М., Романова Е.С., Янкевич Д.С.https://creativecommons.org/licenses/by/4.0https://nmb.abvpress.ru/jour/article/view/445

Dysimmune polyneuropathies are the etiologically heterogeneous group of diseases with autoimmune damage to the peripheral nervous system. The rarity of these diseases doesn’t exclude the possibility of their development or exacerbation in patients infected with SARS‑CoV‑2, which will require timely differential diagnosis and urgent specific therapy. The article summarizes current information on the mechanisms of development, clinical features, diagnosis and management of acute and chronic dysimmune polyneuropathies in the context of the COVID‑19 pandemic.

Дизиммунные полиневропатии представляют собой этиологически гетерогенную группу заболеваний с аутоиммунным поражением периферической нервной системы. Редкость данных заболеваний не исключает возможности их развития или обострения у инфицированных SARS‑CoV‑2 пациентов, что, в свою очередь, потребует проведения своевременной дифференциальной диагностики и неотложной интенсивной и специфической терапии. В статье обобщены актуальные на данный момент сведения, касающиеся механизмов развития, особенностей клинической картины, диагностики и тактики ведения острых и хронических дизиммунных полиневропатий в условиях пандемии COVID‑19.

COVID‑19coronavirus infectionSARS‑CoV‑2Guillain–Barré syndromedisimmune polyneuropathiesCOVID‑19коронавирусная инфекцияSARS‑CoV‑2синдром Гийена–Барредизиммунные полиневропатииRizvanova A.S., Grishina D.A., Suponeva N.A. Clinical heterogeneity of chronic inflammatory demyelinating polyneuropathy: difficulties. Almanakh klinicheskoy mediciny = Almanac of Clinical Medicine 2020;(48):56–64. (In Russ.)DOI: 10.18786/2072-0505-2020-48-007.Ризванова А.С., Гришина Д.А., Супонева Н.А. Клиническая гетерогенность хронической воспалительной демиелинизирующей полинейропатии: трудности диагностики. Альманах клинической медицины 2020;(48):56–64.Lehmann H.C., Burke D., Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry 2019;90(9):981–7. PMID: 30992333. DOI: 10.1136/jnnp-2019-320314.Ryan M., Ryan S.J. Chronic inflammatory demyelinating polyneuropathy: considerations for diagnosis, management, and population health. Am J Manag Care 2018;24(17 Suppl):S371–9.Sitkali I.V., Kolokolov O.V. Guillain–Barré syndrome. Medicinskiy nauchno-prakticheskiy zhurnal = Medical Scientific and Practical Journal 2019;(11):49. (In Russ.)DOI: 10.26295/OS.2019.59.53.012.Ситкали И.В., Колоколов О.В. Синдром Гийена–Барре. Медицинский научно-практический журнал 2019;(11):49.Gheblawi M., Wang K., Viveiros A. et al. Angiotensin-converting enzyme 2: SARSCoV-2 receptor and regulator of the reninangiotensin system: Celebrating the 20th anniversary of the discovery of ACE2. Circulation Res 2020;126(10): 1456–74. PMID: 32264791. DOI: 10.1161/CIRCRESAHA.120.317015.Hamming I., Timens W., Bulthuis M.L. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS corona virus. A first step in understanding SARS pathogenesis. J Pathol 2004;203(2):631–7. PMID: 15141377. DOI: 10.1002/path.1570.Paniz-Mondolfi A., Bryce C., Grimes Z. et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol 2020;92(7):699–702. PMID: 32314810. DOI: 10.1002/jmv.25915.Baig A.M., Khaleeq A., Ali U., Syeda H. Evidence of the COVID-19 virus targeting the cns: tissue distribution, hostvirus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 2020;11(7):995–8. PMID: 32167747. DOI:10.1021/acschemneuro.0c00122.Cutillo G., Saariaho A.H., Meri S. Physiology of gangliosides and the role of antiganglioside antibodies in human diseases. Cell Mol Immunol 2020;17(4):313–22. PMID: 32152553. DOI: 10.1038/s41423-020-0388-9.Tortorici M.A., Walls A.C., Lang Y. et al. Structural basis for human corona virus attachment to sialic acid receptors. Nat Struct Mol Biol 2019;26(6):481–9. PMID: 31160783. DOI: 10.1038/s41594-019-0233-y.Morsy S. NCAM protein and SARSCoV-2 surface proteins: In-silico hypothetical evidence for the immunopathogenesis of Guillain–Barré syndrome. Med Hypotheses 2020;145:110342. PMID: 33069093. DOI: 10.1016/j.mehy.2020.110342.Park M.D. Macrophages: a Trojan horse in COVID-19? Nat Rev Immunol 2020;20(6):351. PMID: 32303696. DOI: 10.1038/s41577-020-0317-2.Zhang B., Zhou X., Zhu C. et al. Immune phenotyping based on the neutrophil-tolymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19. Front Mol Biosci 2020;7:157. PMID: 32719810. DOI: 10.3389/fmolb.2020.00157.Mehta P., McAuley D.F., Brown M. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;28:395(10229):1033–4. PMID: 32192578. DOI: 10.1016/S0140-6736(20)30628-0.Fu Y., Cheng Y., Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virologica Sinica 2020;35(3):266–71. PMID: 32125642. DOI: 10.1007/s12250-020-00207-4.Bohmwald K., Gálvez N., Ríos M., Kalergis A.M. Neurologic alterations due to respiratory virus infections. Front Cell Neurosci 2018;12:386. PMID: 30416428. DOI: 10.3389/fncel.2018.00386.Aziz M., Fatima R., Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. J Med Virol 2020;92(11):2283–5. PMID: 32343429. DOI: 10.1002/jmv.25948.Tanaka T., Narazaki M., Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harbor Persp Biol 2014;6(10):a016295. PMID 25190079. DOI: 10.1101/cshperspect.a016295.Clinical protocol for the treatment of patients with the new corona virus infection COVID-19 who are inpatient treatment in medical organizations of the state health care system of the city of Moscow. Ed. by A.I. Khripun. Moscow: GBU NIIOZMM DZM, 2020. 28 p. (In Russ.)].Клинический протокол лечения больных новой коронавирусной инфекцией COVID-19, находящихся на стационарном лечении в медицинских организациях государственной системы здравоохранения города Москвы. Под ред. А.И. Хрипуна. M.: ГБУ «НИИОЗММ ДЗМ», 2020. 28 с.Piradov M.A., Suponeva N.A., Grishina D.A. Polyneuropathies: algorithms for diagnosis and treatment. Moscow: Goryachaya Liniya – Telekom, 2019. 248 p. (In Russ.)].Пирадов М.А., Супонева Н.А., Гришина Д.А. Полинейропатии: алгоритмы диагностики и лечения. М.: Горячая линия – Телеком, 2019. 248 с.Suponeva N.A., Piradov M.A., Nikitin S.S. et al. Pathogenetic and prognostic role of autoantibodies to peripheral nerve gangliosides in Guillain–Barré syndrome. Annaly klinicheskoy i eksperimentalnoy nevrologii = Annals of Clinical and Experimental Neurology 2013;7(1):4–11. (In Russ.)].Супонева Н.А., Пирадов М.А., Никитин С.С. и др. Патогенетическая и прогностическая роль аутоантител к ганглиозидам периферических нервов при синдроме Гийена–Барре. Анналы клинической и экспериментальной неврологии 2013;7(1):4–11.Van den Berg B., van der Eijk A.A., Pas S.D. et al. Guillain–Barré syndrome associated with preceding hepatitis E virus infection. Neurology 2014;82(6):491–7. PMID: 24415572. DOI: 10.1212/WNL.0000000000000111.Cappello F. COVID-19 and molecular mimicry: The Columbus’ egg? J Clin Neurosci 2020;77:246. PMID: 32389543. DOI: 10.1016/j.jocn.2020.05.015.Chew F.T., Ong S.Y., Hew C.L. Severe acute respiratory syndrome corona virus and viral mimicry. Lancet 2003;361(9374): 2081. PMID: 32081636. DOI: 10.1016/s0140-6736(03)13652-5.Hahn A.F. Guillain–Barré syndrome. Lancet 1998;352(9128):635–41. PMID: 9746040 DOI: 10.1016/S0140-6736(97)12308-X.Camdessanche J.P., Morel J., Pozzetto B. et al. COVID-19 may induce Guillain–Barré syndrome. Rev Neurol 2020;176(6):516–8. PMID: 32334841. DOI: 10.1016/j.neurol.2020.04.003.Alberti P., Beretta S., Piatti M. et al. Guillain–Barré syndrome related to COVID-19 infection. Neurol Neuroimmunol Neuroinflamm 2020;7(4):e741. PMID: 32350026. DOI: 10.1212/NXI.0000000000000741.El Otmani H., El Moutawakil B., Rafai M.A. et al. Covid-19 and Guillain–Barré syndrome: More than a coincidence! Rev Neurol 2020;176(6):518–9. PMID: 32359804. DOI: 10.1016/j.neurol.2020.04.007.Sedaghat Z., Karimi N. Guillain–Barré syndrome associated with COVID-19 infection: A case report. J Clin Neurosci 2020;76:233–35. PMID: 32312628. DOI: 10.1016/j.jocn.2020.04.062.Abdelnour L., Eltahir Abdalla M., Babiker S. COVID-19 infection presenting as motor peripheral neuropathy. J Formosan Med Assoc 2020;119(6):1119–20. PMID: 32354690. DOI: 10.1016/j.jfma.2020.04.024.Zhao H., Shen D., Zhou H. et al. Guillain–Barré syndrome associated with SARS-CoV-2 infection: Causality or coincidence? Lancet Neurol 2020;19(5):383–4. PMID: 32246917. DOI: 10.1016/S1474-4422(20)30109-5.Caress J.B., Castoro R.J., Simmons Z. et al. COVID-19-associated Guillain–Barré syndrome: The early pandemic experience. Muscle Nerve 2020;62(4):485–91. PMID: 32678460. DOI: 10.1002/mus.27024.Uncini A., Vallat J.M., Jacobs B.C. Guillain–Barré syndrome in SARSCoV-2 infection: an instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psych 2020;91(10):1105–10. PMID: 32855289. DOI: 10.1136/jnnp-2020-324491.Cabrero F.R., Morrison E.H. Miller Fisher Syndrome. StatPearls, 2020. PMID: 29939539. Available at:https://www.ncbi.nlm.nih.gov/books/NBK507717/.Gutiérrez–Ortiz C., Méndez-Guerrero A., Rodrigo-Rey S. et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology 2020;95(5):e601–5. PMID: 32303650.DOI: 10.1212/WNL.0000000000009619.Dinkin M., Gao V., Kahan J. et al. COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. Neurology 2020;95(5):221–3. PMID: 32358218. DOI: 10.1212/WNL.0000000000009700.Lantos J.E., Strauss S.B., Lin E. COVID-19-associated Miller Fisher syndrome: MRI findings. Am J Neuroradiol 2020;41(7):1184–6. PMID: 32467190. DOI: 10.3174/ajnr.A6609.Fernández-Domínguez J., AmeijideSanluis E., García-Cabo C. et al. MillerFisher-like syndrome related to SARSCoV-2 infection (COVID-19). J Neurol 2020;267(9):2495–6. PMID: 32458195. DOI: 10.1007/s00415-020-09912-2.Akhmadeeva L.R., Musakaeva K.R., Lipatova E.E. Demielinizing disease of the nervous system – Miller Fisher syndrome with fatal exposure. Puls = Pulse 2018;20(7):49–52. (In Russ.)]. DOI: 10.26787/nydha-2226-7425-2018-20-7-49-52.Ахмадеева Л.Р., Мусакаева К.Р., Липатова Е.Е. Демиелинизирующее заболевание нервной системы – синдром Миллера Фишера с летальным исходом. Пульс 2018;20(7):49–52.Alberti P., Beretta S., Piatti M. et al. Guillain–Barré syndrome related to COVID-19 infection. Neurol Neuroimmunol Neuroinflamm 2020;7(4):e741. PMID: 32350026. DOI: 10.1212/NXI.0000000000000741.Keyhanian K., Umeton R.P., Mohit B. et al. SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation. J Neuroimmunol 2020;577436. PMID: 33212316. DOI: 10.1016/j.jneuroim.2020.577436.McClafferty B., Umer I., Fye G. et al. Approach to critical illness myopathy and polyneuropathy in the older SARS-CoV-2 patients. J Clin Neurosci 2020;79:241–5. PMID: 33070904. DOI: 10.1016/j.jocn.2020.07.058.Galassi G., Marchioni A. Facing acute neuromuscular diseases during COVID-19 pandemic: focus on Guillain–Barré syndrome. Acta Neurol Belgica 2020;120(5):1067–75. PMID: 32696312. DOI: 10.1007/s13760-020-01421-3.Stein M., Bell M.J., Ang L.C. Hydroxychloroquine neuromyotoxicity. J Rheumatol 2000;27(12):2927–31. PMID: 11128688.Ghasemiyeh P., Borhani-Haghighi A., Karimzadeh I. et al. Major neurologic adverse drug reactions, potential drugdrug interactions and pharmacokinetic aspects of drugs used in COVID-19 patients with stroke: a narrative review. Ther Clin Risk Manag 2020;16:595–605. PMID: 32669846. DOI: 10.2147/TCRM.S259152.Kim J.E., Heo J.H., Kim H.O. et al. Neurological complications during treatment of middle east respiratory syndrome. J Clin Neurol 2017;13(3):227–33. PMID: 28748673. DOI: 10.3988/jcn.2017.13.3.227.Yuki N., Hartung H.P. Guillain–Barré syndrome. New Engl J Med 2012;366(24): 2294–304. PMID: 22694000. DOI: 10.1056/NEJMra1114525.Jacobs B.C., Rothbarth P.H., van der Meché F.G. et al. The spectrum of antecedent infections in Guillain–Barré syndrome: A case-control study. Neurology 1998;51(4):1110–5. DOI: 10.1212/wnl.51.4.1110.Hadden R.D., Karch H., Hartung H.P. et al. Preceding infections, immune factors, and outcome in Guillain–Barré syndrome. Neurology 2001;56(6):758–65. DOI: 10.1212/wnl.56.6.758.Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – First Revision. J Periph Nerv Sys 2010;15(1):1–9. PMID: 20433600. DOI: 10.1111/j.1529-8027.2010.00245.x.Breiner A., Barnett C., Bril V. INCAT disability score: a critical analysis of its measurement properties. Muscle Nerve 2014;50(2):164–9. PMID: 24723454. DOI: 10.1002/mus.24207.Graham R.C., Hughes R.A. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychy 2006;77(8):973–6. PMID: 16574730. DOI: 10.1136/jnnp.2005.081547.Van Nes S.I., Vanhoutte E.K., Van Doorn P.A. et al. Rasch-built Overall Disability Scale (R-ODS) for immunemediated peripheral neuropathies. Neurology 2011;76(4):337–45. DOI: 10.1212/WNL.0b013e318208824b.Vanhoutte E.K., Faber C.G., van Nes S.I. et al. Rasch-built Overall Disability Scale for multifocal motor neuropathy(MMNRODS©). J Perif Nerv Sys 2015;20(3):296–305. PMID: 26329270. DOI: 10.1111/jns.12141.Rajabally Y.A., Goedee H.S., Attarian S., Hartung H.P. Management challenges for chronic dysimmune neuropathies during the COVID-19 pandemic. Muscle Nerve 2020;62(1):34–40. PMID: 32311114. DOI: 10.1002/mus.26896.Kassardjian C.D., Desai U., Narayanaswami P. et al. Practical guidance for managing electromyography requests and testing during the COVID-19 pandemic. Muscle Nerve 2020;62(1):30–3. PMID: 32277763. DOI: 10.1002/mus.26891.Van Schaik I.N., Bril V., van Geloven N. et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): A randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Neurol 2018;17(1):35–46. PMID: 29122523. DOI: 10.1016/S1474-4422(17)30378-2.Gianfrancesco M., Hyrich K.L., Al-Adely S. et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry. Ann Rheum Dis 2020;79(7):859–66. DOI: 10.1136/annrheumdis-2020-217871.Dubbioso R., Nobile-Orazio E., Manganelli F. et al. Dealing with immunemediated neuropathies during COVID-19 outbreak: practical recommendations from the task force of the Italian Society of Neurology (SIN), the Italian Society of Clinical Neurophysiology (SINC) and the Italian Peripheral Nervous System Association(ASNP). Neurological Sci 2020;41(6):1345–48. PMID: 32363507. DOI: 10.1007/s10072-020-04448-9.Goncharova Z.A., Kovaleva N.S. Multifocal motor neuropathy. Sibirskoe meditsinskoe obozrenie = Siberian Medical Review 2017;(1):89–92. (In Russ.) DOI: 10.20333/2500136-2017-1-89-92.Гончарова З.А., Ковалева Н.С. Мультифокальная моторная нейропатия. Сибирское медицинское обозрение 2017;(1):103.Yakovlev A.A., Tarabanova E.S., Smochilin A.G. и др. Paraproteinemic polyneuropathy associated with monoclonal gammopathy of undetermined significance: case description and literature review. Uchenye zapiski SPbGMU im. I.P. Pavlova = The Scientific Notes of IPP-SPSMU 2017;24(3):71–81. (In Russ.)]. DOI: 10.24884/1607-4181-2017-24-3-71-81.Яковлев А.А., Тарабанова Е.С., Смочилин А.Г. и др. Парапротеинемическая полинейропатия, ассоциированная с моноклональной гаммапатией неустановленной этиологии: описание клинического случая и обзор литературы. Ученые записки СПбГМУ им. И.П. Павлова 2017;24(3):71–81.Mehta V., Goel S., Kabarriti R. et al. Case fatality rate of cancer patients with COVID-19 in a New York Hospital System. Cancer Discov 2020;10(7): 935–41. PMID: 32357994. DOI: 10.1158/2159-8290.CD-20-0516.Kristinsson S.Y., Tang M., Pfeiffer R.M. et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematol 2012;97(6):854–8. PMID: 22180421. DOI: 10.3324/haematol.2011.054015.Kristinsson S.Y., Fears T.R., Gridley G. et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 2008;112(9):3582–6. PMID: 18559977. DOI: 10.1182/blood-2008-04-151076.Gonzalez-Lugo J.D., Bachier-Rodriguez L., Goldfinger M. et al. A case series of monoclonal gammopathy of undetermined significance and COVID-19. Brit J Haematol 2020;190(3):e130–3. PMID: 32479664. DOI: 10.1111/bjh.16906.Dispenzieri A. POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management. Am J Hematol 2019;94(7):812–27. PMID: 31012139. DOI: 10.1002/ajh.25495.He H., Fu W., Du J. et al. Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen. Brit J Haematol 2018;181(1):126–8. PMID: 28146276. DOI: 10.1111/bjh.14497Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Resp Med 2020;8(4):420–2. PMID: 32085846. DOI: 10.1016/S2213-2600(20)30076-X.Jacob S., Muppidi S., Guidon A. et al. Guidance for the management of myasthenia gravis (MG) and Lambert–Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci 2020;412:116803. PMID: 32247193. DOI: 10.1016/j.jns.2020.116803.